Editorial: Commercialization and industrialization of pharmacology of infectious diseases: 2022.

Autor: Huang Y; Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States., Nang SC; Department of Microbiology, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, Australia., Lin YW; Department of Microbiology, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, Australia.; Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, VIC, Australia.; Malaya Translational and Clinical Pharmacometrics Group, Faculty of Pharmacy, Universiti Malaya, Kuala Lumpur, Malaysia.; Department of Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Universiti Malaya, Kuala Lumpur, Malaysia.; Certara Drug Development Solutions, Certara, Radnor, PA, United States., Sime F; Centre for Clinical Research, The University of Queensland, Brisbane, QLD, Australia.
Jazyk: angličtina
Zdroj: Frontiers in pharmacology [Front Pharmacol] 2024 Jun 19; Vol. 15, pp. 1438072. Date of Electronic Publication: 2024 Jun 19 (Print Publication: 2024).
DOI: 10.3389/fphar.2024.1438072
Abstrakt: Competing Interests: Author Y-WL was employed by the company Certara. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Databáze: MEDLINE